http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
흡입마취시 Neostigmine 과 Pyridostigmine 이 심혈관 반응에 미치는 영향
강효석,이춘희,이귀용 대한마취과학회 1990 Korean Journal of Anesthesiology Vol.23 No.6
At the end of the operation, residual neuromusular blookade may be antagonized by anticholines-terase (edrophonium, neostigmine and pyridostigmine). Neostigmine is probably commonly used antagonist of nondepolarizing neuromuscular blocking agents. But, because of an apparent longer duration of action and lesser muscarinic effects, pyridos- tigmine has been suggested as possibly superior to neostigmine as an antagonist of nondepolarizing neuromuscular blockade. Accordingly, present study observed the heart rate, systolic and diastolic blood pressure changes following equipotent doses of pyridostigmine and neostigmine given with glycopyrrolate in inhalation anesthesia (halothane and enflurane). Eighty patients were randomly divided in four groups as follows: Group I: halothane, glycopyrrolate + neostigmine Group II: halothane, glycopyrrolate + pyridostigmine Group IIl: enflurane, glycopyrrolate + neostigmine Group IV: enflurane, glycopyrrolate +pyridostigmine The results were as follows: 1) In halothane and enflurane anesthesia, the changes in heart rate were significant in each group after 4 minutes and especially, the group I, III showed more decrease than the group II, IV. 2) Tachycardia were observd until 6 minutes after administration of anticholinesterase in each group. Bradycardia were appeared at 6 minutes in the group I, IIl and at 14 minutes in the group II, IV and, each group showed bradycardia which continued over 20 mintes. 3) Even though the decrease of systolic and diastolic blood pressure showed transiently with time, there were no significant difference in the changes in ach group. 4) When the same anticholinesterase was administered, the cardiovascular responses were no significant difference between the halothane and enfurane anesthesia. In conclusion, pyridostigmine with glycopyrrolate seems to produce minimal changes in the cadiovascular responses in halothane and enflurane anesthesia.
강효석 한국외국어대학교 지식출판콘텐츠원 글로벌경영연구소 2010 글로벌경영연구 = Journal of global business research Vol.22 No.1
STX Shipbuilding has not only been one of the fastest growing company in Korea, but also played a major role in the development of Korea’s world-leading shipbuilding industry. As of year-end 2006, the company’s order backlog and shipbuilding capacity ranked sixth in the world, and its exports topped US$ 1 billion. It has recently acquired ownership of Aker Yards ASA, the world’s fourth largest shipbuilder in Europe. With this attempt, the company expects to establish a beachhead in cruise and ferries market where most Korean shipbuilders have not achieved competitive advantage as yet. In this case study, we perform financial analysis of STX Shipbuilding to see if the company is financially secure. We also proceed to its stock valuation using various valuation techniques. The case material to be used in the classroom was prepared at the end of 2007.
강효석,서재웅 한국외국어대학교 지식출판콘텐츠원 글로벌경영연구소 2011 글로벌경영연구 = Journal of global business research Vol.23 No.3
This paper investigates the effects of divestitures announcements on shareholder wealth. Analyzing a sample of 208 divestitures during 1999~2008, we find that ordinary divestitures earn significant positive CARs than divestitures subsequent to backdoor listings. Divestitures to become holding companies have significantly higher CARs than divestitures with different purposes. It is also evidenced the abnormal announcement returns of focusing-divestitures higher than those of non-focusing divestitures. However, we could not support the hypothesis that the announcement effects of spin-offs are different from those of non spin-offs.
Current therapeutic agents and anesthetic considerations for diabetes mellitus
강효석 대한마취통증의학회 2012 Korean Journal of Anesthesiology Vol.63 No.3
As the incidence of diabetes mellitus (DM) continues to increase worldwide, more diabetic patients will be presented for surgery and anesthesia. This increase of DM is a consequence of the rise in new patients of type 2 DM, and is likely attributable to rapid economic development, improved living standards, aging population, obesity, and lack of exercise. The primary goal of management in DM is to delay, or prevent the macro- and microvascular complications by achieving good glycemic control. More understanding of the pathophysiology of DM has contributed to the advance of new pharmacological approaches. In addition to the conventional therapy for DM, glucagon-like peptide-1 (GLP-1) mimetics, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZDs), and insulin analogues are currently available effective hypoglycemic agents for the management of the patients with DM in the perioperative period and also consider the adverse effects of newly introduced agents that need more clinical observations.